FDA RBM Guidance is Still Misinterpreted
October 11th 2016As biopharma companies continue to explore and experience ways in which risk-based monitoring is implemented, the process of such can be misconstrued. Peter Schiemann elaborates on some of the current issues of RBM interpretation and implementation.
Top Three Translation Strategies for Global Trials
October 6th 2016Globalization has increasingly become a part of the clinical trial landscape as pharma sponsors conduct trials internationally. With language barriers being among the challenges of this process, translation management is now a must during the planning phase of a global trial.
Challenges with Running Clinical Research in China
October 6th 2016Clinical research in China has shown potential as many biopharma companies look to enter the market, though the infrastructure is lacking. Peter Schiemann, PhD conveys his perspectives on the challenges that sponsors are facing in China.
European Pediatric Informed Consent and AF: Current Status of Country Requirements
The Pediatric Working Group of EUCROF launched an initiative to achieve standardization of generic Informed Consent Form and Assent Form templates within European countries. The differences are noted based on a prior survey.
GSK Addresses Clinical Outcomes Through Patient-Centric Studies
October 4th 2016The need for biopharma to demonstrate the value of medical products is changing trial design in order to generate real world data. Dr. Catherine Bonuccelli of GSK discusses the Salford Lung Study, its patient-centric design and how it differs from randomized clinical trials.